Whohoo! By March 2025, more than 300 experts from 140 organisations in 38 countries have joined the Liver Health Helix. Launched in 2021 to support the dissemination and impact of A-TANGO, the Helix is an international open innovation community of specialists in the fields of liver disease, in particular, from cirrhosis research, general hepatology, drug manufacturing, bioinformatics, and related disciplines. The Helix supports A-TANGO's ambition to develop a novel therapy for liver failure, also called acute-on-chronic liver failure (ACLF), and is managed by Burcu Kiper from A-TANGO partner Crowdhelix (CHX). Please click here to create an account and then search for and join the "Liver Health Helix".

Who truly conducted the first clinical trial can be debated, but historical records suggest it happened in biblical times. Prof. Cornelius Engelmann (MD, PhD) from the Charité - Universitätsmedizin Berlin, who supervises the clinical G-TAK trial of A-TANGO, will give an all-encompassing Masterclass lecture about "Clinical Trial Design - Strategies, Procedures, Pitfalls & Lessons Learned from A-TANGO" for invited participants, clinicians, and early-career scientists (ECS) of the A-TANGO and DECISION-Project on Wednesday, 26 March 2025, from 4-5 pm CET. Selected slides from his presentation will be available for download from the "Training & E-Learning" page after the event - stay tuned!

Yaqrit welcomes Troels Jordansen as its new CEO. With over 30 years of international healthcare experience spanning pharmaceuticals, medical devices, cellular therapy, and biotech, Troels brings a strong commercial background in sales, marketing, investor relations, and business development. Having co-founded start-ups and led public companies, he has raised over €200 million in funding and closed deals exceeding €500 million. His global expertise will also be instrumental in driving A-TANGO’s innovation. Read the related press release.